Guardian Wealth Advisors LLC NC Increases Stake in Zoetis Inc. (NYSE:ZTS)

Guardian Wealth Advisors LLC NC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 23.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,281 shares of the company’s stock after buying an additional 246 shares during the period. Guardian Wealth Advisors LLC NC’s holdings in Zoetis were worth $209,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ZTS. JPMorgan Chase & Co. increased its stake in shares of Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after buying an additional 279,092 shares during the period. Harbor Capital Advisors Inc. raised its holdings in Zoetis by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 9,569 shares of the company’s stock worth $1,559,000 after purchasing an additional 234 shares in the last quarter. Czech National Bank raised its holdings in Zoetis by 6.0% in the fourth quarter. Czech National Bank now owns 97,822 shares of the company’s stock worth $15,938,000 after purchasing an additional 5,531 shares in the last quarter. Fiduciary Alliance LLC bought a new position in Zoetis in the fourth quarter worth about $663,000. Finally, Trust Co. of Toledo NA OH raised its holdings in Zoetis by 5.1% in the fourth quarter. Trust Co. of Toledo NA OH now owns 1,431 shares of the company’s stock worth $233,000 after purchasing an additional 70 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.1%

NYSE ZTS opened at $159.96 on Monday. The business has a fifty day moving average price of $157.27 and a 200 day moving average price of $165.95. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market cap of $71.37 billion, a P/E ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the prior year, the company earned $1.38 EPS. The firm’s revenue was up 1.4% compared to the same quarter last year. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on ZTS. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Morgan Stanley dropped their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Finally, UBS Group dropped their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $212.13.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. 0.18% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.